Nitzan Rosenfeld

Nitzan Rosenfeld has developed foundational ctDNA quantification and analysis methods that have become standard tools for monitoring therapy response, including techniques exploiting the characteristic fragmentation patterns of tumor-derived cell-free DNA to enhance detection sensitivity. His research at the Cancer Research UK Cambridge Institute has established key principles of ctDNA biology including the relationship between fragment size and tumor origin, enabling size-based enrichment strategies that improve detection limits. His methodological innovations have been critical for making ctDNA therapy monitoring practical and reliable in clinical settings.